1. Intravenous Thrombolysis in Acute Myocardial Infarction
Ohman E. Magnus , MD, FCCP, Harrington Robert A. , MD, Cannon Christopher P. , MD, Agnelli Giancarlo , MD, Cairns John A. , MD, Kennedy J.Ward , MD 
CHEST 
Volume 119, Issue 1, Pages 253S-277S (January 2001)
DOI: /chest.119.1_suppl.253S
Copyright © 2001 The American College of Chest Physicians Terms and Conditions

2. Figure 1
Structure of t-PA and mutant forms. Reprinted from Brener and Topol15 with permission.
CHEST  , 253S-277SDOI: ( /chest.119.1_suppl.253S)
Copyright © 2001 The American College of Chest Physicians Terms and Conditions

3. Figure 2
Patency rates (TIMI grade 2 or 3 flow) in patientstreated with streptokinase, accelerated alteplase, standard-dosealteplase, or anistreplase for acute MI, vs control subjects. Adaptedfrom Granger et al,42 with permission.
CHEST  , 253S-277SDOI: ( /chest.119.1_suppl.253S)
Copyright © 2001 The American College of Chest Physicians Terms and Conditions

4. Figure 3
Incidence of TIMI grade 2 or 3 flow 90 min afterTNK-tPA or accelerated alteplase treatment in the TIMI-10B trial.Reprinted from Cannon et al,22 with permission.
CHEST  , 253S-277SDOI: ( /chest.119.1_suppl.253S)
Copyright © 2001 The American College of Chest Physicians Terms and Conditions

5. Figure 4
Dosing schedule of weight-adjusted TNK-tPA used inthe ASSENT-2 trial. Reprinted with permission fromLancet.127
CHEST  , 253S-277SDOI: ( /chest.119.1_suppl.253S)
Copyright © 2001 The American College of Chest Physicians Terms and Conditions